Guggenheim reiterated their positive rating on shares of Theravance Biopharma Inc. (NASDAQ:TBPH) in a research report released on Monday. They currently have a $40.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on TBPH. Leerink Swann reaffirmed a buy rating on shares of Theravance Biopharma in a research note on Saturday, June 4th. Zacks Investment Research raised Theravance Biopharma from a hold rating to a buy rating and set a $26.00 price objective on the stock in a research note on Tuesday, July 12th. Bank of America Corp. lowered Theravance Biopharma from a neutral rating to an underperform rating in a research note on Wednesday, August 3rd. Finally, Evercore ISI initiated coverage on Theravance Biopharma in a research note on Monday, August 29th. They issued a buy rating and a $41.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Theravance Biopharma presently has an average rating of Hold and a consensus price target of $34.50.

Theravance Biopharma (NASDAQ:TBPH) opened at 35.54 on Monday. The company has a 50 day moving average price of $28.83 and a 200 day moving average price of $23.24. Theravance Biopharma has a 12 month low of $10.56 and a 12 month high of $35.60. The firm’s market capitalization is $1.70 billion.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative net margin of 471.82% and a negative return on equity of 70.79%. Analysts anticipate that Theravance Biopharma will post ($4.03) earnings per share for the current fiscal year.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of the stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $27.46, for a total value of $1,348,890.12. Following the completion of the transaction, the executive vice president now directly owns 241,686 shares in the company, valued at $6,636,697.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brett K. Haumann sold 4,491 shares of the stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $27.99, for a total value of $125,703.09. Following the completion of the transaction, the senior vice president now owns 188,293 shares of the company’s stock, valued at $5,270,321.07. The disclosure for this sale can be found here. 4.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of TBPH. Schwab Charles Investment Management Inc. increased its position in Theravance Biopharma by 35.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 113,650 shares of the biopharmaceutical company’s stock valued at $2,579,000 after buying an additional 29,512 shares in the last quarter. Paloma Partners Management Co purchased a new position in Theravance Biopharma during the second quarter valued at approximately $255,000. Panagora Asset Management Inc. increased its position in Theravance Biopharma by 19.2% in the second quarter. Panagora Asset Management Inc. now owns 212,115 shares of the biopharmaceutical company’s stock valued at $4,813,000 after buying an additional 34,203 shares in the last quarter. Scion Asset Management LLC increased its position in Theravance Biopharma by 18.2% in the second quarter. Scion Asset Management LLC now owns 325,000 shares of the biopharmaceutical company’s stock valued at $7,374,000 after buying an additional 50,000 shares in the last quarter. Finally, Barclays PLC increased its position in Theravance Biopharma by 3,421.9% in the second quarter. Barclays PLC now owns 13,489 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 13,106 shares in the last quarter. Hedge funds and other institutional investors own 69.89% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPH

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.